Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Placebo-Controlled, Randomized, Double Blind, Adaptive Dose Trial of the Safety and Efficacy of Inhaled AZD1419 in Adults With Eosinophilic, Moderate to Severe Asthma

NCT02898662 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02898662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02898662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Placebo-Controlled, Randomized, Double Blind, Adaptive Dose Trial of the Safety and Efficacy of Inhaled AZD1419 in Adults With Eosinophilic, Moderate to Severe Asthma
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
October 12, 2016
Completion date
September 25, 2018
Enrollment
81 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

asthma